Design Therapeutics, Inc.
DSGN
$9.77
$0.839.28%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -7.30% | 2.35% | |||
| Gross Profit | 7.30% | -2.35% | |||
| SG&A Expenses | -19.02% | 15.67% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.47% | 5.64% | |||
| Operating Income | 10.47% | -5.64% | |||
| Income Before Tax | 10.93% | -7.72% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 10.93% | -7.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 10.93% | -7.72% | |||
| EBIT | 10.47% | -5.64% | |||
| EBITDA | 10.56% | -5.72% | |||
| EPS Basic | 11.08% | -7.53% | |||
| Normalized Basic EPS | 11.11% | -7.53% | |||
| EPS Diluted | 11.08% | -7.53% | |||
| Normalized Diluted EPS | 11.11% | -7.53% | |||
| Average Basic Shares Outstanding | 0.16% | 0.18% | |||
| Average Diluted Shares Outstanding | 0.16% | 0.18% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||